
CHMP Recommends Approval for UPLINZA to Treat NMOSD
Back in June of this year, the FDA granted approval to UPLINZA to reduce attacks in patients with anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD). Now, the…